Why the study?
Does perindopril reduce cardiovascular events in diabetic patients with coronary artery disease without heart failure?
Population
n=1502 diabetic patients with known coronary artery disease and without heart failure
Comparison
Perindopril 8 mg once daily vs Placebo
Design
RCT, randomized, double-blinded
Follow-up
median of 4.3 years
Authors
Loading...
Does not support routine perindopril use in this subgroup; extends EUROPA findings but leaves benefit in diabetics open.
Does perindopril reduce cardiovascular events in diabetic patients with coronary artery disease without heart failure?
In diabetic patients with stable coronary artery disease without heart failure, perindopril showed a non-significant trend towards reducing major cardiovascular events, consistent with the benefit seen in the broader EUROPA trial population.
Daly et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: